|
Market Research Report
Immune/Inflammatory Disease: Early-Stage R&D Technologies and Dealmaking
|
Immune/Inflammatory Disease: Early-Stage R&D Technologies and Dealmaking published by Decision Resources, Inc. in May, 2009. This report consists of 24 Pages and the price starts from US $ 3450.
Abstract
Introduction
Today' s leading autoimmune/infl ammatory disease drugs are blockbusters, but
what are the remaining unmet needs and next opportunities? Dealmaking patterns
indicate that Big Pharma continues to look to small technology companies to
tap opportunities to treat underserved diseases and offer improved
administration options. While the value of the novel agents in development
remains unproved, earlystage platforms and pipelines house the next
innovations in these disease states.
Get the Answers You Need to Shape Your Strategy
- Although effi cacious, current therapies for infl ammatory and autoimmune
diseases do not successfully treat all patients. What novel mechanisms of
action are in development? What technologies offer treatment potential?
- Much of the innovation in drug discovery and design occurs in small
companies. What companies are developing novel approaches to treat infl
ammatory diseases? What collaborations have they forged with Big Pharma?
- Although the infl ammatory cascade is central to most of the autoimmune
diseases, the specifi c etiology of many diseases remains unknown. What are
companies doing to further the understanding of these diseases?
Scope
- Current market: 2008 sales, market-leading products, leading companies.
- Novel targets for drug development: MAP kinases, Janus kinases, toll-like
receptors, novel interleukins, NF-κB, PDE4.
- Novel technologies for drug development: RNA therapeutics, stem-cell
therapy.
- Development and dealmaking data: 8 tables that identify developmental
compounds and industry and academic alliances.
- Company profi les: Archemix, Array BioPharma, Cellzome, Dynavax, Regulus
Therapeutics.
Companies Mentioned in This Spectrum Report
- Abbott
- Adeona Pharmaceuticals
- Amgen
- Anacor Pharmaceuticals
- Anesiva
- AnGes MG
- Archemix
- Ardea
- Array BioPharma
- AstraZeneca
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Celgene
- Cellzome
- Centocor
- Cytokine Pharmasciences
- Cytos Biotechnology
- Dainippon Sumitomo
- Dynavax
- Eisai
- Eli Lilly
- Genzyme
- GlaxoSmithKline
- Glenmark Pharmaceuticals
- Hutchison Medipharma
- Idera Pharmaceuticals
- Incyte
- Institute of Medicinal Molecular Design
- Kemia
- Ligand
- Merck
- Merck Serono
- Mitsubishi Tanabe
- MorphoSys
- Novartis
- Nycomed
- Osiris
- Otsuka Pharmaceutical
- Pfi zer
- Reata Pharmaceuticals
- Regulus Therapeutics
- Rigel Pharmaceuticals
- Roche
- RXi Pharmaceuticals
- Sanofi -Aventis
- Schering-Plough
- Sigma-Aldrich
- Silence Therapeutics
- Synta Pharmaceuticals
- Takeda
- Transcription Factor Therapeutics
- Verona Pharma
- Vertex Pharmaceuticals
- VGX Pharmaceuticals
- Wyeth
- Znomics
Table of Contents
- Executive Summary 5
- Strategic Considerations 5
- Stakeholder Implications 5
- Introduction 6
- What Market Awaits Innovative Therapies? 7
- Novel Approaches to Infl ammation/Autoimmune Disease Treatment 9
- Novel Targets 9
- MAP Kinases 9
- Jak 11
- Toll-Like Receptors 12
- Novel Interleukins 13
- Nuclear Factor-Kappa B 15
- Phosphodiesterase 4 15
- Novel Technologies 16
- RNA-Based Therapeutics 16
- Stem-Cell Therapy 17
- Company Profi les 18
- Archemix 18
- Array BioPharma 18
- Cellzome 18
- Dynavax 19
- Regulus Therapeutics 19
- Outlook 20
Tables
- 1. Descriptions of Infl ammatory and Autoimmune Diseases 6
- 2. Top-Selling Autoimmune and Anti-Infl ammatory Treatments, 2008
8
- 3. Common Immune Treatments and their Targets 10
- 4. MAP Kinase Agents in Clinical Development for Autoimmune and Infl
ammatory Diseases 11
- 5. Jak Kinase Agents in Development for Autoimmune and Infl ammatory
Diseases 12
- 6. Toll-Like Receptor Agents in Development for Autoimmune and Infl
ammatory Diseases 13
- 7. IL-12, IL-17, and IL-23 Agents in Development for Autoimmune and Infl
ammatory Diseases 14
- 8. NF-κB Agents in Development for Autoimmune and Infl ammatory
Diseases 15
- 9. PDE4 Agents in Development for Autoimmune and Infl ammatory Diseases
16
- 10. Select Deals in Autoimmune and Infl ammatory Disease Drug Development
21
- 11. Select Academic Collaborations in Autoimmune and Infl ammatory Disease
Drug Development 22
Figures
- 1. Worldwide Sales of Agents to Treat Infl ammatory and Autoimmune
Diseases, 2003-2008 7
- 2. Market Share of the Autoimmune and Infl ammatory Disease Market by
Company, 2008 8
|
